k bipolar manic-depressive patient, developed while on lithium prophylaxis, akathisia at therapeutic serum lithium levels and subsequently bucco-linguo-masticatory dyskinesia. The authors propose that differential involvement of dopamine systems may account for the transition from akathisia to tardive dyskinesia. In the light of a brief review of literature, a prospective study of akathisia and tardive dyskinesia seems justified.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0303-8467(84)90074-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Research Advances in Terahertz Technology for Skin Detection.
Photobiomodul Photomed Laser Surg
January 2025
School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
With the continuous development of Terahertz technology and its high sensitivity to water, Terahertz technology has been widely applied in various research areas within the field of biomedicine, such as research onskin wounds and burns, demonstrating numerous advantages and potential. The aim of this study is to summarize and conclude the current research status of Terahertz radiation in skin wounds, burns, and melanoma. Additionally, it seeks toreveal the development status of Terahertz in skin wound models and analyze the short comings of Terahertz in detecting such models at the present stage.
View Article and Find Full Text PDFFuture Directions in the Treatment of Low-Grade Gliomas.
Cancer J
January 2025
Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL.
There is major interest in deintensifying therapy for isocitrate dehydrogenase-mutant low-grade gliomas, including with single-agent cytostatic isocitrate dehydrogenase inhibitors. These efforts need head-to-head comparisons with proven modalities, such as chemoradiotherapy. Ongoing clinical trials now group tumors by intrinsic molecular subtype, rather than classic clinical risk factors.
View Article and Find Full Text PDFManagement of Low-Grade Gliomas.
Cancer J
January 2025
From the Division of Neuro-Oncology, Department of Neurology and the Herbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians & Surgeons and NewYork-Presbyterian, New York, NY.
The term "low-grade glioma" historically refers to adult diffuse gliomas that exhibit a less aggressive course than the more common high-grade gliomas. In the current molecular era, "low-grade" refers to World Health Organization central nervous system grade 2 gliomas almost always with an isocitrate dehydrogenase (IDH) mutation (astrocytomas and oligodendrogliomas). The term "lower-grade gliomas" has emerged encompassing grades 2 and 3 IDH-mutant astrocytomas and oligodendrogliomas, to acknowledge that histological grade is not as important a prognostic factor as molecular features, and distinguishing them from grade 4 glioblastomas, which lack an IDH mutation.
View Article and Find Full Text PDFRecent Advancements and Future Perspectives on Molecular Biomarkers in Adult Lower-Grade Gliomas.
Cancer J
January 2025
From the Department of Radiation Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH.
There has been a significant paradigm shift in the clinical management of lower-grade glioma patients given the recent updates to the 2021 World Health Organization classification along with long-term results from randomized phase III clinical trials. As a result, we are now better able to diagnose and assign patients to the most appropriate treatment course. This review provides a comprehensive summary of the most robust and reliable molecular biomarkers for adult lower-grade gliomas and discusses current challenges facing this patient population that future correlative biology studies combined with advancements in technologies could help overcome.
View Article and Find Full Text PDF[The impact of innate immune response on the efficacy of oncolytic viruses].
Vopr Virusol
December 2024
Oncolytic viruses represent a promising class of immunotherapeutic agents for the treatment of malignant tumors. The proposed mechanism of action of various oncolytic viruses has initially been explained by the ability of such viruses to selectively lyse tumor cells without damaging healthy ones. Recently, there have emerged more studies determining the effect of the antiviral immunostimulating mechanisms on the effectiveness of treatment in cancer patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!